Gary Nachman
Stock Analyst at Raymond James
(2.16)
# 2,539
Out of 4,814 analysts
101
Total ratings
55.07%
Success rate
-0.45%
Average return
Main Sectors:
Stocks Rated by Gary Nachman
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| ABBV AbbVie | Reiterates: Outperform | $218 → $220 | $170.16 | +29.29% | 14 | Feb 3, 2025 | |
| SDGR Schrödinger | Maintains: Outperform | $25 → $28 | $26.19 | +6.91% | 5 | Nov 13, 2024 | |
| ALNY Alnylam Pharmaceuticals | Maintains: Outperform | $275 → $298 | $232.96 | +27.92% | 7 | Nov 1, 2024 | |
| LENZ LENZ Therapeutics | Initiates: Outperform | $37 | $24.27 | +52.45% | 1 | Sep 27, 2024 | |
| ACHV Achieve Life Sciences | Initiates: Strong Buy | $20 | $2.23 | +796.86% | 1 | Sep 27, 2024 | |
| PCRX Pacira BioSciences | Maintains: Outperform | $41 → $37 | $25.97 | +42.47% | 13 | Jul 31, 2024 | |
| BLCO Bausch + Lomb | Initiates: Outperform | $19 | $12.04 | +57.87% | 1 | Jul 10, 2024 | |
| AMGN Amgen | Reinstates: Market Perform | n/a | $273.68 | - | 1 | Mar 28, 2024 | |
| SRRK Scholar Rock Holding | Initiates: Strong Buy | $30 | $29.87 | +0.44% | 5 | Mar 28, 2024 | |
| AQST Aquestive Therapeutics | Initiates: Outperform | $7 | $2.58 | +171.84% | 1 | Mar 28, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $3 | $0.52 | +472.41% | 1 | Mar 28, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Market Perform | n/a | $100.34 | - | 11 | Sep 29, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Market Perform | $5 → $4 | $7.14 | -43.98% | 5 | Mar 3, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $35 → $30 | $3.88 | +674.19% | 4 | Mar 1, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $70 → $67 | $28.53 | +134.84% | 2 | Feb 23, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $40 → $32 | $2.46 | +1,203.46% | 1 | Feb 22, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Market Perform | $16 → $14 | $7.58 | +84.82% | 2 | Feb 17, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $90 → $75 | $9.16 | +718.78% | 4 | Nov 14, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Market Perform | $43 → $40 | $7.45 | +437.27% | 8 | Nov 9, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Market Perform | $11 → $10 | $13.31 | -24.87% | 1 | Nov 7, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $40 → $30 | $16.93 | +77.20% | 2 | Nov 4, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $810 → $750 | $2.75 | +27,172.73% | 2 | Aug 11, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Market Perform | $15 → $8 | $4.71 | +69.85% | 2 | Aug 10, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Market Perform | $20 → $21 | $23.47 | -10.52% | 5 | May 11, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $24 → $14 | $2.56 | +446.88% | 2 | Jun 14, 2018 |
AbbVie
Feb 3, 2025
Reiterates: Outperform
Price Target: $218 → $220
Current: $170.16
Upside: +29.29%
Schrödinger
Nov 13, 2024
Maintains: Outperform
Price Target: $25 → $28
Current: $26.19
Upside: +6.91%
Alnylam Pharmaceuticals
Nov 1, 2024
Maintains: Outperform
Price Target: $275 → $298
Current: $232.96
Upside: +27.92%
LENZ Therapeutics
Sep 27, 2024
Initiates: Outperform
Price Target: $37
Current: $24.27
Upside: +52.45%
Achieve Life Sciences
Sep 27, 2024
Initiates: Strong Buy
Price Target: $20
Current: $2.23
Upside: +796.86%
Pacira BioSciences
Jul 31, 2024
Maintains: Outperform
Price Target: $41 → $37
Current: $25.97
Upside: +42.47%
Bausch + Lomb
Jul 10, 2024
Initiates: Outperform
Price Target: $19
Current: $12.04
Upside: +57.87%
Amgen
Mar 28, 2024
Reinstates: Market Perform
Price Target: n/a
Current: $273.68
Upside: -
Scholar Rock Holding
Mar 28, 2024
Initiates: Strong Buy
Price Target: $30
Current: $29.87
Upside: +0.44%
Aquestive Therapeutics
Mar 28, 2024
Initiates: Outperform
Price Target: $7
Current: $2.58
Upside: +171.84%
Mar 28, 2024
Initiates: Outperform
Price Target: $3
Current: $0.52
Upside: +472.41%
Sep 29, 2023
Initiates: Market Perform
Price Target: n/a
Current: $100.34
Upside: -
Mar 3, 2023
Maintains: Market Perform
Price Target: $5 → $4
Current: $7.14
Upside: -43.98%
Mar 1, 2023
Maintains: Outperform
Price Target: $35 → $30
Current: $3.88
Upside: +674.19%
Feb 23, 2023
Maintains: Outperform
Price Target: $70 → $67
Current: $28.53
Upside: +134.84%
Feb 22, 2023
Maintains: Outperform
Price Target: $40 → $32
Current: $2.46
Upside: +1,203.46%
Feb 17, 2023
Downgrades: Market Perform
Price Target: $16 → $14
Current: $7.58
Upside: +84.82%
Nov 14, 2022
Maintains: Outperform
Price Target: $90 → $75
Current: $9.16
Upside: +718.78%
Nov 9, 2022
Maintains: Market Perform
Price Target: $43 → $40
Current: $7.45
Upside: +437.27%
Nov 7, 2022
Maintains: Market Perform
Price Target: $11 → $10
Current: $13.31
Upside: -24.87%
Nov 4, 2022
Maintains: Outperform
Price Target: $40 → $30
Current: $16.93
Upside: +77.20%
Aug 11, 2022
Maintains: Outperform
Price Target: $810 → $750
Current: $2.75
Upside: +27,172.73%
Aug 10, 2022
Maintains: Market Perform
Price Target: $15 → $8
Current: $4.71
Upside: +69.85%
May 11, 2020
Maintains: Market Perform
Price Target: $20 → $21
Current: $23.47
Upside: -10.52%
Jun 14, 2018
Maintains: Outperform
Price Target: $24 → $14
Current: $2.56
Upside: +446.88%